<DOC>
	<DOCNO>NCT00680758</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Everolimus may stop growth tumor cell block enzymes need cell growth . Giving one drug ( combination chemotherapy ) together everolimus may kill tumor cell . PURPOSE : This phase I trial study side effect best dose cisplatin , paclitaxel , everolimus give together treatment patient metastatic breast cancer .</brief_summary>
	<brief_title>Cisplatin , Paclitaxel , Everolimus Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish safety profile maximum tolerate dose combination cisplatin , paclitaxel , everolimus patient metastatic breast cancer . Secondary - To explore antitumor activity regimen , term response rate time progression patient . OUTLINE : This multicenter study . Patients receive cisplatin intravenously ( IV ) 1 hour paclitaxel IV 1 hour day 1 , 8 , 15 . Patients receive oral everolimus day 1 , 8 , 15 , 21 . Courses repeat every 4 week absence disease progression unaccepted toxicity . After completion study therapy , patient follow 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive mammary carcinoma Stage IV disease No locally recurrent breast cancer Patients HER2/neu overexpressing tumor must receive prior trastuzumab ( Herceptin® ) firstline treatment metastatic breast cancer Patients estrogen receptor progesterone receptorexpressing tumor must receive prior endocrine therapy ( i.e. , aromatase inhibitor , fulvestrant , tamoxifen , ovarian ablation ) firstline treatment metastatic breast cancer No symptomatic brain metastasis Patients history brain metastasis must clinically stable take steroid therapeutic anticonvulsant CYP3A4 modifier Patients asymptomatic brain metastasis prophylactic convulsants CYP3A4 modifier eligible Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 01 Life expectancy ≥ 6 month ANC ≥ 1000/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN ( 3 time ULN liver metastasis present ) SGOT SGPT ≤ 1.5 time ULN ( 3 time ULN liver metastasis present ) Alkaline phosphatase ≤ 3 time ULN liver metastasis present Able swallow retain oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Must diseasefree prior invasive cancer &gt; 5 year exception completely resect basal cell squamous cell carcinoma skin successfully treat cervical carcinoma situ No malabsorption syndrome , disease significantly affect gastrointestinal function , ulcerative colitis No uncontrolled intercurrent illness include , limited : Ongoing active infection require parenteral antibiotic Impairment lung function ( i.e. , chronic obstructive pulmonary disease lung condition require oxygen therapy ) Symptomatic New York Heart Association class IIIIV congestive heart failure Unstable angina pectoris , angioplasty , stenting , myocardial infarction within past 6 month Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg ) Clinically significant cardiac arrhythmia ( i.e. , multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment ) Uncontrolled diabetes Psychiatric illness/social situation would preclude compliance study requirement No known history uncontrolled symptomatic neuropathy ≥ grade 2 No hypersensitivity paclitaxel , drug use vehicle Cremophor , Chinese hamster ovary cell product , recombinant human antibody PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior treatment Must exceed total cumulative dose lifetime exposure doxorubicin hydrochloride ≤ 360 mg/m² epirubicin hydrochloride ≤ 640 mg/m² At least 2 week since prior investigational drug No prior resection stomach small bowel No 4 prior chemotherapy regimen metastatic set This restriction include endocrine therapy single agent biologic therapy ( i.e. , trastuzumab ) Concurrent radiotherapy painful bone metastasis area impend bone fracture allow long radiotherapy initiate prior study entry No concurrent trastuzumab No concurrent endocrine therapy No concurrent CYP3A4 modifiers No concurrent herbal supplement No concurrent anticancer therapy ( chemotherapy , radiotherapy , surgery , immunotherapy , hormonal therapy , biological therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>